Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients

Acta Pharmacologica Sinica

Volumn 29, Issue 2, 2008, Pages 252-258

  Wang, Jie ^a   Bao, Yu Qian ^a   Hu, Cheng ^a   Zhang, Rong ^a   Wang, Cong Rong ^a   Lu, Jun Xi ^a   Jia, Wei Ping ^a   Xiang, Kun San ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

ATP binding cassette transporter subfamily A number 1; Pharmacogenetics; Rosiglitazone; Single nucleotide polymorphisms

Indexed keywords

ABC TRANSPORTER A1; INSULIN; ROSIGLITAZONE;

ADULT; ALLELE; ARTICLE; DIABETIC PATIENT; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HOMEOSTASIS; HOMOZYGOTE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN VARIANT; RISK; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DNA; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; WAIST-HIP RATIO;

EID: 38749126467     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00744.x     Document Type: Article

References (37)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005 365 : 1333 46.
2. DeFronzo RA. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 1992 35 : 389 97.
3. Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2007 18 : 18 25.
4. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001 276 : 37731 4.
5. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999 16 : 179 92.
6. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002 51 : 2796 803.
7. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmaco-genomics and individualized drug therapy. Annu Rev Med 2006 57 : 119 37.
8. Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006 80 : 657 67.
9. Kang ES, Park SY, Kim HJ, Ahn CW, Nam M, Cha BS, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005 28 : 1139 44.
10. Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-γ2 gene variant: results from the troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004 27 : 1365 8.
11. Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003 26 : 825 31.
12. Wolford JK, Yeatts KA, Dhanjal SK, Black MH, Xiang AH, Buchanan TA, et al. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 2005 54 : 3319 25.
13. Kang ES, Park S Y, Kim HJ, Kim CS, Ahn CW, Cha BS, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005 78 : 202 8.
14. Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007 92 : 1502 9.
15. Attie AD. ABCA1: at the nexus of cholesterol, HDL and atherosclerosis. Trends Biochem Sci 2007 32 : 172 9.
16. Daimon M, Ji G, Saitoh T, Oizumi T, Tominaga M, Nakamura T, et al. Large-scale search of SNPs for type 2 DM susceptibility genes in a Japanese population. Biochem Biophys Res Commun 2003 302 : 751 8.
17. Daimon M, Kido T, Baba M, Oizumi T, Jimbu Y, Kameda W, et al. Association of the ABCA1 gene polymorphisms with type 2 DM in a Japanese population. Biochem Biophys Res Commun 2005 329 : 205 10.
18. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007 13 : 340 7.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 15 : 539 53.
20. Matthews DR, Hosker J P, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 9.
21. Scheen AJ, Lefebvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999 22 : 1568 77.
22. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 43.
23. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007 30 : 217 23.
24. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005 76 : 887 93.
25. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005 21 : 263 5.
26. Weinshilboum RM, Wang L. Pharmacogenetics and pharmaco-genomics: development, science, and translation. Annu Rev Genomics Hum Genet 2006 7 : 223 45.
27. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 368 : 1096 105.
28. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001 7 : 161 71.
29. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra I P, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001 7 : 53 8.
30. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995 44 : 863 70.
31. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004 53 Suppl 1 : S119 24.
32. Poitout V, Robertson RP. Mini review: secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002 143 : 339 42.
33. Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K, et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 2001 103 : 1198 205.
34. Soro-Paavonen A, Naukkarinen J, Lee-Rueckert M, Watanabe H, Rantala E, Soderlund S, et al. Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL. J Lipid Res 2007 48 : 1409 16.
35. Evans D, Beil FU. The association of the R219K polymorphism in the ATP-binding cassette transporter 1 (ABCA1) gene with coronary heart disease and hyperlipidaemia. J Mol Med 2003 81 : 264 70.
36. Brunham LR, Singaraja RR, Pape TD, Kejariwal A, Thomas PD, Hayden MR. Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene. PLoS Genet 2005 1 : e83.
37. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 2004 114 : 1343 53.